Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: identification of rifampicin as a neuroprotectant

British Journal of Pharmacology

Volumn 175, Issue 2, 2018, Pages 284-300

  López García, Isabel ^a   Gerő, Domokos ^a   Szczesny, Bartosz ^a   Szoleczky, Petra ^a   Olah, Gabor ^a   Módis, Katalin ^a   Zhang, Kangling ^b   Gao, Jungling ^a   Wu, Ping ^a   Sowers, Lawrence C ^b   DeWitt, Doug ^a   Prough, Donald S ^a   Szabo, Csaba ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; LACTATE DEHYDROGENASE; RIFAMPICIN; 3-(4,5-DIMETHYL-2-THIAZOLYL)-2,5-DIPHENYL-2H-TETRAZOLIUM BROMIDE; HYDROGEN PEROXIDE; NEUROPROTECTIVE AGENT; TETRAZOLIUM;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL DEATH; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG SCREENING; FETUS; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM INJURY; NEURAL STEM CELL; NEURITE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; RAPID STRETCH INJURY; RAT; ANIMAL; DISEASE MODEL; DRUG EFFECT; MECHANICAL STRESS; METABOLISM; MITOCHONDRION; PRECLINICAL STUDY; PROCEDURES; TRAUMATIC BRAIN INJURY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BRAIN INJURIES, TRAUMATIC; CELL DEATH; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDROGEN PEROXIDE; L-LACTATE DEHYDROGENASE; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; RIFAMPIN; STRESS, MECHANICAL; TETRAZOLIUM SALTS;

EID: 85003550190     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13642     Document Type: Article

References (62)

1. Abdul-Muneer PM, Chandra N, Haorah J (2015). Interactions of oxidative stress and neurovascular inflammation in the pathogenesis of traumatic brain injury. Mol Neurobiol 51: 966–979.
2. Arundine M, Aarts M, Lau A, Tymianski M (2004). Vulnerability of central neurons to secondary insults after in vitro mechanical stretch. J Neurosci 24: 8106–8123.
3. Bell JD, Park E, Ai J, Baker AJ (2009). PICK1-mediated GluR2 endocytosis contributes to cellular injury after neuronal trauma. Cell Death Differ 16: 1665–1680.
4. Biagini G, Zoli M, Torri C, Boschi S, Vantaggiato G, Ballestri M et al. (1997). Protective effects of delapril, indapamide and their combination chronically administered to stroke-prone spontaneously hypertensive rats fed a high-sodium diet. Clin Sci (Lond) 93: 401–411.
5. Bramlett HM, Dietrich WD (2007). Progressive damage after brain and spinal cord injury: pathomechanisms and treatment strategies. Prog Brain Res 161: 125–124.
6. Brouwer MC, van de Beek D (2013). Intensified intravenous rifampicin in tuberculous meningitis. Lancet Infect Dis 13: 2–3.
7. Chazotte B (2011). Labeling Nuclear DNA with Hoechst 33342. CSHL. 1: pdf.prot5557.
8. Chao C, Zatarain JR, Ding Y, Coletta C, Mrazek AA, Druzhyna N et al. (2016). Cystathionine-beta-synthase inhibition for colon cancer: enhancement of the efficacy of aminooxyacetic acid via the prodrug approach. Mol Med. doi:10.2119/molmed.2016.00102. [Epub ahead of print]
9. Chong WS, Hyun CL, Park MK, Park JM, Song HO, Park T et al. (2012). Midazolam protects B35 neuroblastoma cells through Akt-phosphorylation in reactive oxygen species derived cellular injury. Korean J Anesthesiol 62: 166–171.
10. Croslan DR, Schoell MC, Ford GD, Pulliam JV, Gates A, Clement CM et al. (2008). Neuroprotective effects of neuregulin-1 on B35 neuronal cells following ischemia. Brain Res 1210: 39–47.
11. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
12. Dailey L, Basilico C (2001). Coevolution of HMG domains and homeodomains and the generation of transcriptional regulation by Sox/POU complexes. J Cell Physiol 186: 315–328.
13. Dewan MC, Mummareddy N, Wellons JC 3rd, Bonfield CM (2016). (2016). Epidemiology of global pediatric traumatic brain injury: qualitative review. World Neurosurg 91: 497–509.
14. DeWitt DS, Jenkins LW, Prough DS (1995). Enhanced vulnerability to secondary ischemic insults after experimental traumatic brain injury. New Horiz 3: 376–383.
15. DeWitt DS, Prough DS (2009). Blast-induced brain injury and posttraumatic hypotension and hypoxemia. J Neurotrauma 26: 877–887.
16. Di Giovanni S, Movsesyan V, Ahmed F, Cernak I, Schinelli S, Stoica B et al. (2005). Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc Natl Acad Sci U S A 102: 8333–8338.
17. Dranka BP, Benavides GA, Diers AR, Giordano S, Zelickson BR, Reily C et al. (2011). Assessing bioenergetic function in response to oxidative stress by metabolic profiling. Free Radic Biol Med 51: 1621–1635.
18. Engel DC, Slemmer JE, Vlug AS, Maas AI, Weber JT (2005).Combined effects of mechanical and ischemic injury to cortical cells: secondary ischemia increases damage and decreases effects of neuroprotective agents. Neuropharmacology 49: 985–995.
19. Fukuda K, Hirooka K, Mizote M, Nakamura T, Itano T, Shiraga F (2010). Neuroprotection against retinal ischemia–reperfusion injury by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 51: 3629–3638.
20. Gero D, Szabo C (2015). Salvage of nicotinamide adenine dinucleotide plays a critical role in the bioenergetic recovery of post-hypoxic cardiomyocytes. Br J Pharmacol 172: 4817–4832.
21. Gero D, Szoleczky P, Suzuki K, Modis K, Olah G, Coletta C et al. (2013). Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction. Diabetes 62: 953–964.
22. Glass TF, Reeves B, Sharp FR (2004). The impact of excitotoxic blockade on the evolution of injury following combined mechanical and hypoxic insults in primary rat neuronal culture. Neurobiol Dis 17: 378–384.
23. Gollapudi S, Jaidka S, Gupta S (2003). Molecular basis of rifampicin-induced inhibition of anti-CD95-induced apoptosis of peripheral blood T lymphocytes: the role of CD95 ligand and FLIPs. J Clin Immunol 23: 11–22.
24. Harford-Wright E, Thornton E, Vink R (2010). Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury. Neurosci Lett 481: 26–29.
25. Hiebert JB, Shen Q, Thimmesch AR, Pierce JD (2015). Traumatic brain injury and mitochondrial dysfunction. Am J Med Sci 350: 132–138.
26. Hoffman SW, Rzigalinski BA, Willoughby KA, Ellis EF (2000). Astrocytes generate isoprostanes in response to trauma or oxygen radicals. J Neurotrauma 17: 415–420.
27. Kilic U, Kilic E, Lingor P, Yulug B, Bähr M (2004). Rifampicin inhibits neurodegeneration in the optic nerve transection model in vivo and after 1-methyl-4-phenylpyridinium intoxication in vitro. Acta Neuropathol 108: 65–68.
28. Kochanek PM, Jackson TC, Ferguson NM, Carlson SW, Simon DW, Brockman EC et al. (2015). Emerging therapies in traumatic brain injury. Semin Neurol 35: 83–100.
29. Lamprecht MR, Elkin BS, Kesavabhotla K, Crary JF, Hammers JL, Huh JW et al. (2016). Strong correlation of genome-wide expression after traumatic brain injury in vitro and in vivo implicates a role for SORLA. J Neurotrauma [Epub ahead of print].
30. Laskowitz D, Grant G (eds) (2016). Translational Research in Traumatic Brain Injury. CRC Press/Taylor and Francis Group: Boca Raton (FL).
31. Li Y, Hawkins BE, DeWitt DS, Prough DS, Maret W (2010). The relationship between transient zinc ion fluctuations and redox signaling in the pathways of secondary cellular injury: relevance to traumatic brain injury. Brain Res 1330: 131–141.
32. Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J et al. (2004). Randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc 52: 381–387.
33. Módis K, Coletta C, Erdélyi K, Papapetropoulos A, Szabo C (2013). Intramitochondrial hydrogen sulfide production by 3-mercaptopyruvate sulfurtransferase maintains mitochondrial electron flow and supports cellular bioenergetics. FASEB J 27: 601–611.
34. Morrison B 3rd, Elkin BS, Dollé JP, Yarmush ML (2011). In vitro models of traumatic brain injury. Annu Rev Biomed Eng 13: 91–126.
35. Morrison SJ (2011). Neuronal differentiation: proneural genes inhibit gliogenesis. Curr Biol 11: R349–R351.
36. Muramoto M, Yamazaki T, Nishimura S, Kita Y (2003). Detailed in vitro pharmacological analysis of FK506-induced neuroprotection. Neuropharmacology 45: 394–403.
37. Nicholas D, Tang H, Zhang Q, Rudra J, Xu F, Langridge W et al. (2015). Quantitative proteomics reveals a role for epigenetic reprogramming during human monocyte differentiation. Mol Cell Proteomics 14: 15–29.
38. Olsen JV, Schwartz JC, Griep-Raming J, Nielsen ML, Damoc E, Denisov E et al. (2004). Dual pressure linear ion trap Orbitrap instrument with very high sequencing speed. Mol Cell Proteomics 8: 2759–2769.
39. Park IH, Yeum CE, Chae GT, Lee SB (2008). Effect of rifampicin to inhibit rapamycin-induced autophagy via the suppression of protein phosphatase 2 A activity. Immunopharmacol Immunotoxicol 30: 837–849.
40. Pearn ML, Niesman IR, Egawa J, Sawada A, Almenar-Queralt A, Shah SB et al. (2016). Pathophysiology associated with traumatic brain injury: current treatments and potential novel therapeutics. Cell Mol Neurobiol [Epub ahead of print].
41. Peeters W, van den Brande R, Polinder S, Brazinova A, Steyerberg EW, Lingsma HF et al. (2015). Epidemiology of traumatic brain injury in Europe. Acta Neurochir 157: 1683–1696.
42. Rodrigues CM, Stieers CL, Keene CD, Ma X, Kren BT, Low WC et al. (2000). Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. J Neurochem 75: 2368–2379.
43. Skotak M, Wang F, Chandra N (2012). An in vitro injury model for SH-SY5Y neuroblastoma cells: effect of strain and strain rate. J Neurosci Meth 205: 159–168.
44. Smeda JS, Daneshtalab N (2011). The effects of poststroke captopril and losartan treatment on cerebral blood flow autoregulation in SHRsp with hemorrhagic stroke. J Cereb Blood Flow Metab 31: 476–485.
45. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al. (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76–85.
46. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44 (Database Issue): D1054–D1068.
47. Szabo C (2005). Mechanisms of cell necrosis. Crit Care Med 33 (12 Suppl): S530–S534.
48. Tang K, Peng G, Qiao Y, Song L, Jing N (2015). Intrinsic regulations in neural fate commitment. Dev Growth Differ 57: 109–120.
49. Te Brake L, Dian S, Ganiem AR, Ruesen C, Burger D, Donders R et al. (2015). Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob Agents 45: 496–503.
50. Tomiyama T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H et al. (1996). Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem 271: 6839–6844.
51. Tyndale RF, Hales TG, Olsen RW, Tobin AJ (1994). Distinctive patterns of GABAA receptor subunit mRNAs in 13 cell lines. J Neurosci 14: 5417–5428.
52. Wang E, Gao J, Yang Q, Parsley MO, Dunn TJ, Zhang L et al. (2012). Molecular mechanisms underlying effects of neural stem cells against traumatic axonal injury. J Neurotrauma 29: 295–312.
53. Wang N, Xu M, Wang P, Li L (2010). Development of mass spectrometry-based shotgun method for proteome analysis of 500 to 5000 cancer cells. Anal Chem 82: 2262–2271.
54. Wasil M, Halliwell B, Moorhouse CP (1988). Scavenging of hypochlorous acid by tetracycline, rifampicin and some other antibiotics: a possible antioxidant action of rifampicin and tetracycline? Biochem Pharmacol 37: 775–778.
55. Werner C, Hoffman WE, Kochs E, Rabito SF, Miletich DJ (1991). Captopril improves neurologic outcome from incomplete cerebral ischemia in rats. Stroke 22: 910–914.
56. White LA, Keane RW, Whittemore SR (1994). Differentiation of an immortalized CNS neuronal cell line decreases their susceptibility to cytotoxic T cell lysis in vitro. J Neuroimmunol 49: 135–143.
57. Whittemore SR, White LA (1993). Target regulation of neuronal differentiation in a temperature-sensitive cell line derived from medullary raphe. Brain Res 615: 27–40.
58. Wu P, Tarasenko YI, Gu Y, Huang LY, Coggeshall RE, Yu Y (2002). Region-specific generation of cholinergic neurons from fetal human neural stem cells grafted in adult rat. Nat Neurosci 5: 1271–1278.
59. Yerramasetti R, Gollapudi S, Gupta S (2002). Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J Clin Immunol 22: 37–47.
60. Yuan L, Hassan BA (2014). Neurogenins in brain development and disease: an overview. Arch Biochem Biophys 558: 10–13.
61. Yulug B, Hanoglu L, Kilic E, Schabitz WR (2014). Rifampicin: an antibiotic with brain protective function. Brain Res Bull 107: 37–42.
62. Yulug B, Kilic U, Kilic E, Bähr M (2004). Rifampicin attenuates brain damage in focal ischemia. Brain Res 996: 76–80.